Precigen, Inc.
corporate_fare Company Profile
Precigen, Inc. (NASDAQ:PGEN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for PGEN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for PGEN spans 10-Q, 8-K, 4, SCHEDULE 13D/A.
Recent high-impact activity:
- Precigen Posts $35.8M Q3 Profit as Papzimeos Revenue Hits $72.9M
- PAPZIMEOS Revenue Jumps 37% to $72.9M; Precigen Turns Cash Flow Positive a Quarter Early
- FDA Grants Platform Technology Designation to Precigen's AdenoVerse
- Precigen Achieves First Profitable Quarter with Strong Papzimeos Sales
- Precigen Posts First-Ever Profit on $53.1M PAPZIMEOS Revenue, Sees Cash Flow Break-Even by Year-End
Financial Snapshot
Short Interest & Short Volume
8.56 days to coverFINRA reported short interest of 44,908,434 shares in PGEN as of the October 30, 2026 settlement, a 3.2% decrease from the prior period — about 8.6 days to cover at its recent average daily volume. On November 20, 2026, 46.9% of PGEN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for PGEN, detected from its recent SEC filings · based on capital-structure filings through 2026-06-24.
Incentive Plan Amendment Approved · 7 Million Additional Shares Authorized
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →